trial · primary record
pertuzumab
HER2-positive Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 63 |
| Primary completion | 2026-04-20 |
| Primary endpoint | Progression Free Survival (MBC Cohort) |
| Registry ID | NCT01730833 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:06.571Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01730833
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pertuzumab · approval
- pertuzumab · compound